

organized by:



in collaboration with:



under the auspices of:



# IMMUNOTHERAPY bridge 2020

Virtual meeting  
December 2<sup>nd</sup> - 3<sup>rd</sup>, 2020

# GENERAL INFORMATION

---



## CME PROVIDER AND ORGANIZING AGENCY:

3P Solution Srl

Via Marradi 3, 20123 Milan

Phone +39 02 36631574 | Fax +39 02 36631640

Cell. +39 391 4986841

[www.3psolution.it](http://www.3psolution.it)

[info@3psolution.it](mailto:info@3psolution.it)

[info@melanomabridge.org](mailto:info@melanomabridge.org)

## OFFICIAL LANGUAGE:

The official language is English

## REGISTRATION:

This year the registration will be **free of charge** for all HCPs, but only registered attendees will be admitted to the meeting.

To register:

- go to: [www.melanomabridge.org/registration-key-dates.php](http://www.melanomabridge.org/registration-key-dates.php) and click on REGISTER NOW
- directly through the link: [www.vincentonair.com](http://www.vincentonair.com)

Please, contact the Organizing Secretariat for any further information:  
[registration@melanomabridge.org](mailto:registration@melanomabridge.org)

# SCIENTIFIC RATIONAL

---

Over the last few years, an extensive research has improved our understanding of tumor immunology and enabled the development of novel treatments that can harness the patient's immune system and prevent immune escape.

Through numerous clinical trials and real-world experience, a large amount of evidence of the potential for long-term survival with immunotherapy agents has been accumulated in various types of malignancy, starting from melanoma to extend to other tumors.

The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L)1 inhibitor in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Study results have highlighted a number of recurring observations, including the immunotherapy potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The successes of the immune-oncology is strongly correlated with the immune system ability of "memory" and adaptability, to improve the time of survival and without selecting resistant form of tumoral cells. Another advantage is that the efficacy of immunotherapeutics does not seem to be particularly influenced by histology and mutations.

First session of the congress will be jointly organized with the Society for ImmunoTherapy of Cancer (SITC) and dedicated to the biomarkers (tissue biomarkers, microbiome, immuno-metabolism).

Hence, the state of the art of immunotherapy from the clinical point of view in various types of malignancies will be exhaustively discussed (lung, head and neck, ovarian, cervical and endometrial, breast, prostate, gastrointestinal tract and Lymphomas) and on targeting cancer through stimulation of innate immunity with intratumorals.

Then the "Great Debate" session, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed from different points of view:

- Antitumoral vaccination is still an option: yes or not?
- Is anti PD-1 / PDL1 a backbone for immunotherapy combination: yes or not?
- Do we need an innovative studies design and is overall survival the endpoint? Point of view of Academia, "regulators", Company

Conclusions will be drawn after the last session on Neo-Adjuvant in different types of cancer.

In order to disclose and stimulate the discussion of new approaches and strategies in the field of immunotherapy and based on the increasing success of "Immunotherapy Bridge" events over the years, a panel of international faculty will join the congress that will be held as webinar in December 2020.

# PRELIMINARY SCIENTIFIC PROGRAM

Wednesday, Dec 2<sup>nd</sup>, 2020



01:00 pm	Introduction and objectives <b>Paolo A. Ascierto</b>
	<b>SITC SESSION BIOMARKERS</b> <i>Chairpersons: Paolo A. Ascierto, Bernard Fox, Patrick Hwu</i>
01:10 pm	Multiplex Immunofluorescence assay development: current status and future directions <b>Janis M. Taube</b>
01:25 pm	Integrating multiomics in the practice of diagnostic pathology <b>Carlo Bifulco</b>
01:40 pm	Leveraging other genomes as potential response biomarkers: the microbiome <b>Jennifer McQuade</b>
01:55 pm	Biomarkers Task Force <b>Chrystal Paulos</b>
02:10 pm	Chewing through the fat: metabolic regulation of anti-tumor immunity <b>Susan M. Kaech</b>
02:25 pm	Best of SITC for clinical development and trials <b>Paolo A. Ascierto</b>
02:40 pm	Discussion on biomarkers <b>Paolo A. Ascierto, Bernard Fox, Patrick Hwu</b>
03:10 pm	Break**
	<b>SESSION 2 TRENDS IN IMMUNOTHERAPY</b> <i>Chairpersons: Paolo A. Ascierto, Bruno Daniele, John Haanen</i>
03:25 pm	Kidney Cancer <b>Camillo Porta</b>
03:55 pm	<b>SYMPOSIUM – Combined Therapy</b> The role of combined therapies across tumor types <b>Paolo A. Ascierto, Cesare Gridelli, Sara Lonardi</b>
04:45 pm	Break**
05:00 pm	The role of combined chemo-immunotherapy in first-line treatment of advanced NSCLC <b>Cesare Gridelli</b>

\*invited speaker

\*\*Not included in the CME accredited program

# PRELIMINARY SCIENTIFIC PROGRAM

Wednesday, Dec 2<sup>nd</sup>, 2020



- 05:15 pm | Breast cancer immunotherapy: biomarkers and clinical benefit  
**Leisha Emens**
- 05:30 pm | Immunotherapy for HPV related Head&Neck cancer  
**Robert Ferris**
- 05:45 pm | Therapeutic strategies to sensitize prostate cancer to immunotherapy:  
from bedside to bench and back  
**Akash Patnaik**
- 06:00 pm | Break\*\*
- 06:15 pm | Adaptive metabolic rewiring of the tumor microenvironment impedes  
efficacy of IDO blockade in ovarian cancer  
**Kunle Odunsi**
- 06:30 pm | Immunotherapy in GI Cancer  
**Fortunato Ciardiello**
- 06:45 pm | Merkel Cell carcinoma  
**Paolo A. Ascierto**
- 07:00 pm | Discussion on trends in immunotherapy  
**Paolo A. Ascierto, Bruno Daniele, John Haanen**

2020

*\*invited speaker*

*\*\*Not included in the CME accredited program*

# PRELIMINARY SCIENTIFIC PROGRAM

Thursday, Dec 3<sup>rd</sup>, 2020



## SESSION 3

### DRIVERS OF IMMUNE RESPONSES

*Chairpersons: Paolo A. Ascierto, Alfredo Budillon, Luigi Buonaguro*

- 01:00 pm Mechanisms of immunotherapy response and resistance  
**Jerome Galon**
- 01:15 pm Breast cancer, radiation and immunotherapy  
**Silvia Formenti**
- 01:30 pm Lymphomas  
**John Timmerman**
- 01:45 pm Revolt of the T cell system against anti-PD1 immunotherapy  
**Samir N. Khleif**
- 02:00 pm Break\*\*
- 02:15 pm Transcriptional imprints of inherited T-cell regulome modulating immunotherapy outcomes  
**Tomas Kirchhoff**
- 02:30 pm T cell differentiation states in the irradiated tumor microenvironment that drive responses to CTLA-4 blockade  
**Sandra Demaria**
- 02:45 pm Discussion on drivers of immune responses  
**Paolo A. Ascierto, Daniele Bruno, John Haanen**

- 03:15 pm **SYMPOSIUM** Non-Melanoma Skin Cancer  
Non-melanoma skin cancer – updates of new developments at ASCO and ESMO 2020  
**Dirk Schadendorf**  
**Paolo A. Ascierto**

- 04:05 pm Break\*\*

## GREAT DEBATE SESSION

*Chairpersons: Paolo A. Ascierto, Bernard Fox, Patrick Hwu, Igor Puzanov*

- 04:20 pm Antitumoral vaccination is still an option: yes or not?  
**Lisa H. Butterfield, Olivera J. Finn**
- 04:45 pm Discussion on "Antitumoral vaccination is still an option: yes or not?"  
**Paolo A. Ascierto, Bernard Fox, Patrick Hwu, Igor Puzanov**
- 04:55 pm Is anti PD-1 / PDL1 a backbone for immunotherapy combination: yes or not?  
**Ryan J. Sullivan, Joshua Brody**

*\*invited speaker*

*\*\*Not included in the CME accredited program*

# PRELIMINARY SCIENTIFIC PROGRAM

Thursday, Dec 3<sup>rd</sup>, 2020



- 05:25 pm Discussion on "Is anti PD-1 / PDL1 a backbone for immunotherapy combination: yes or no?"  
**Paolo A. Ascierto, Bernard Fox, Patrick Hwu, Igor Puzanov**
- 05:35 pm Break\*\*
- 05:50 pm Do we need an innovative studies design and is overall survival the endpoint? Point of view of Academia, "regulators", Company  
**Francesco Perrone, Raj Puri\*, John Goldberg**
- 06:35 pm Discussion on "Do we need an innovative studies design and is overall survival the endpoint?"  
**Paolo A. Ascierto, Bernard Fox, Patrick Hwu, Igor Puzanov**
- 06:45 pm What we will do on Monday?  
**Sanjiv S. Agarwala**
- 07:00 pm Break\*\*
- SESSION**  
**NEOADJUVANT IMMUNOTHERAPY ACROSS CANCERS**  
*Chairpersons: Paolo A. Ascierto, Elizabeth M. Burton*
- 07:15 pm From the clinic to the lab: investigating mechanisms of response and resistance to immune checkpoint therapy  
**Padmanee Sharma**
- 07:30 pm Neoadjuvant immunotherapy in Breast Cancer  
**Leisha Emens**
- 07:45 pm Neoadjuvant immunotherapy for operable non-small cell lung cancer: lessons learned and current challenges  
**Tina Cascone**
- 08:00 pm Neoadjuvant therapy in melanoma  
**Rodabe N. Amaria**
- 08:15 pm Towards a Pan-tumor scoring system of pathologic response to immunotherapy  
**Janis M. Taube**
- 08:30 pm Discussion on Neo Adjuvant immunotherapy across cancers  
**Paolo A. Ascierto, Elizabeth M. Burton**
- 09:00 pm Conclusions  
**Paolo A. Ascierto, Bernard Fox, Patrick Hwu, Igor Puzanov**

\*invited speaker

\*\*Not included in the CME accredited program

# PRESIDENCY

---

**Paolo A. Ascierto**

Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute Fondazione "G. Pascale", Naples, Italy

**Bernard A. Fox**

Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center, Portland, Oregon, US

**Patrick Hwu**

MD, President & CEO, Moffitt Cancer Center, Tampa, Florida, US

**Igor Puzanov**

Director, Early Phase Clinical Trials Program, Chief of Melanoma, Co-Leader, CCSG Experimental Therapeutics Program, Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, US

# SCIENTIFIC BOARD

**Sanjiv S. Agarwala**

Professor & Chief, Haematology & Oncology, St Luke's University Hospital and Temple University, Bethlehem, Pennsylvania, US

**Paolo A. Ascierto**

Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute Fondazione "G. Pascale", Naples, Italy

**Carlo Bifulco**

Medical Director of Oncological Molecular Pathology and Pathology Informatics, Providence Oregon Regional Laboratory and Earle A. Chiles Research Institute, Portland, Oregon, US

**Elizabeth M. Burton**

Director, Melanoma Research Planning & Development, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Lisa H. Butterfield**

Adjunct Professor, Microbiology and Immunology, UCSF, VP, PICI Research & Development, Parker Institute for Cancer Immunotherapy, San Francisco, California, US

**Corrado Caracò**

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Sandra Demaria**

Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology and Adjunct Professor at Department of Pathology, Weill Cornell Medical College and NYU School of Medicine, New York City, New York, US

**Reinhard Dummer**

Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland



# SCIENTIFIC BOARD

---

**Bernard A. Fox**

Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center, Portland, Oregon, US

**Jerome Galon**

Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

**Claus Garbe**

University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology, Eberhard- Karls University Tuebingen, Germany

**Omid Hamid**

Chief of Research/ Immuno-Oncology and Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, Los Angeles, California, US

**Patrick Hwu**

MD, President & CEO, Moffitt Cancer Center, Tampa, Florida, US

**Giuseppe Masucci**

Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

**Iman Osman**

Associate Dean for Translation Research and Director of the Melanoma Program, New York University Langone, Medical School, New York City, New York, US

**Giuseppe Palmieri**

President Italian Melanoma Intergroup (IMI), Head of Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy

**Michael Postow**

Memorial Sloane Kettering Cancer Center, New York City, New York, US

**Igor Puzanov**

Director, Early Phase Clinical Trials Program, Chief of Melanoma, Co-Leader, CCSG Experimental Therapeutics Program, Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, US

**Magdalena Thurin**

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland, US

**Tara Withington**

Executive Director of Society of Immunotherapy for Cancer (SITC), Milwaukee, Wisconsin, US

# FACULTY

**Sanjiv S. Agarwala**

Professor & Chief, Haematology & Oncology, St Luke's University Hospital and Temple University, Bethlehem, Pennsylvania, US

**Rodabe Amaria**

Associate Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Paolo A. Ascierto**

Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute Fondazione "G. Pascale", Naples, Italy

**Carlo Bifulco**

Medical Director of Oncological Molecular Pathology and Pathology Informatics, Providence Oregon Regional Laboratory and Earle A. Chiles Research Institute, Portland, Oregon, US

# FACULTY

---

**Joshua Brody**

Associate Professor, The Mount Sinai Cancer Center, New York, NY, US

**Daniele Bruno**

Director of Clinical Oncology Unit, Hospital "del Mare", ASL Napoli 1 Centro, Naples, Italy

**Alfredo Budillon**

Chief, Experimental Pharmacology Unit, Department of Translational Research, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Luigi Buonaguro**

Director, Innovative Immunological Models Department of Research, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Elizabeth M. Burton**

Director, Melanoma Research Planning & Development, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Lisa H. Butterfield**

Adjunct Professor, Microbiology and Immunology, UCSF, VP, PICI Research & Development, Parker Institute for Cancer Immunotherapy, San Francisco, California, US

**Tina Cascone**

Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Fortunato Ciardiello**

Professor of Medical Oncology, Director Medical Oncology and Hematology Division, University "Luigi Vanvitelli", Naples, Italy

**Sandra Demaria**

Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology and Adjunct Professor at Department of Pathology, Weill Cornell Medical College and NYU School of Medicine, New York City, New York, US

**Leisha Emens**

Professor of Medicine, Director of Translational Immunotherapy for the Women's Cancer Research Center, UPMC Hillman Cancer Center/Magee Women's Hospital, Co-Leader, Hillman Cancer Immunology/Immunotherapy Program, Pittsburgh, Pennsylvania, US

**Robert Ferris**

Director, UPMC Hillman Cancer Center, Professor of Oncology, Associate Vice Chancellor for Cancer Research, Co-Director, Tumor Microenvironment Center Professor of Otolaryngology, of Immunology, and of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, US

**Olivera J. Finn**

Distinguished Professor, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, US

**Silvia C. Formenti**

Professor & Chief Chairman of Radiation Oncology - Weill Cornell Medical College, New York City, New York, US

**Bernard A. Fox**

Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center, Portland, Oregon, US

**Jerome Galon**

Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

**Cesare Gridelli**

Chief of Division of Medical Oncology, "S.G. Moscati" Hospital, Avellino, Italy

**John Goldberg**

Senior Vice President, Clinical Development, Oncorus, Cambridge, Massachusetts, US

**John B. Haanen**

Consultant Medical Oncologist, CSO Immunotherapy and Staff Scientist in the Division of Immunology, Professor of Translational Immunotherapy of Cancer, Leiden University Medical Centre, Amsterdam, The Netherlands

# FACULTY

---

**Patrick Hwu**

MD, President & CEO, Moffitt Cancer Center, Tampa, Florida, US

**Susan M. Kaech**

Professor & Director, Nomis Center for Immunobiology and Microbial Pathogenesis, The Salk Institute, University of California, San Francisco, CA, US

**Samir N. Khleif**

Director of the Loop Immuno-Oncology Laboratory, Biomedical Scholar and Professor of Oncology, Georgetown University Medical School, Washington, DC, US

**Tomas Kirchhoff**

Associate Professor, Department of Population Health Associate Professor, Department of Environmental Medicine, Perlmutter Cancer Center, New York City, New York, US

**Sara Lonardi**

Head of Early Phase Clinical Trial Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy

**Jennifer McQuade**

Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, US

**Kunle Odunsi**

Cancer Center Deputy Director, Executive Director - Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

**Akash Patnaik**

Assistant Professor of Medicine, Hematology and Oncology, Director of Laboratory for Developmental Therapeutics Attending Physician, Genitourinary Oncology Program, The University of Chicago Comprehensive Cancer, Chicago, Illinois, US

**Chrystal M. Paulos**

Associate Professor and Endowed Peng Chair, Department of Microbiology and Immunology Hollings Cancer Center, Medical University of South Carolina (MUSC), Charleston, South Carolina, US

**Francesco Perrone**

Director of Clinical Trials Unit, National Cancer Institute Fondazione "G. Pascale", Naples, Italy

**Camillo Porta**

Department of Biomedical Sciences and Human Oncology, University of Bari "A. Moro", Chief, Division of Medical Oncology, Policlinico Consorziale di Bari

**Raj Puri**

Director of Division of Cellular and Gene Therapies, Food and Drug Administration Bethesda, Maryland, US

**Igor Puzanov**

Director, Early Phase Clinical Trials Program, Chief of Melanoma, Co-Leader, CCSG Experimental Therapeutics Program, Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, NY, US

**Dirk Schadendorf**

Director & Chair, Department of Dermatology & Director, Comprehensive Cancer Center at University Hospital, Essen, Germany

**Padmanee Sharma**

Professor, Departments of Genitourinary Medical Oncology and Immunology, Division of Cancer Medicine, UT MD Anderson Cancer Center, Houston, Texas, US

**Ryan J. Sullivan**

Associated Director Hematology-Oncology Dept, Massachusetts General Hospital, Boston, MA, US

**Janis M. Taube**

Director, Division of Dermatopathology, Professor of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, US

**John Timmerman**

Professor of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine, UCLA Medical Center, Los Angeles, California, CA



# E.C.M.

*Commissione Nazionale Formazione Continua*



## CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Standard Provider (code 327, authorized on October 15th, 2012).

3P Solution owns the responsibility for the content, quality and ethical correctness of this CME activity.

Melanoma Bridge congress has been accredited (ID CME 327-307189) with 18 CME credits with a formative technical-professional objective "Technical professional content (knowledge and competences) specifications of each profession, of all specialization and ultra-specialist activity. Rare disease", belonging to formative technical-professional objective area, for the following professions: medical doctors, pharmacists, biologists, nurses.

The number of attendees can not exceed the number of accredited participants.

In order to receive credits, participants must:

1. Attend at least 90% of the accredited CME sessions (attendance check);
2. Complete the CME test by answering at least 75% of the questions correctly
3. Complete the evaluation form

## MY ECM

Age.na.s activated MyEcm service (personalized page available to any health professional), which enables you to:

1. Consult the CME events offer;
2. Refer to the summary of events attended and earned credits;
3. Provide an assessment of courses organized by the Provider.

To access online services please log on to <http://ape.agenas.it/professionisti/myecm>.

If this meeting fulfilled your expectations, please click on  and give your assessment.

Immunotherapy Bridge is sponsored by an unrestricted grant from:

---

PLATINUM SPONSOR



GOLD SPONSOR



SILVER SPONSOR



SPONSOR

